Market Overview

UPDATE: Deutsche Bank Raises PT to $95 on Gilead Sciences on Latest Data

Related GILD
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Bristol-Myers Seeks Approval for HIV Combo Drug - Analyst Blog
Don't Panic Over Recent Tech Turmoil (Fox Business)

Deutsche Bank reiterated its Buy rating on Gilead Sciences (NASDAQ: GILD) and increased its price target from $75 to $95.

Deutsche Bank said, "At the liver meeting today, Bristol ns5a and GILD nuke showed 100pct SVR with or without ribavirin, in patients that showed up for follow-up. So far 68/82 patients are at SVR12 timeframe and it was noted all 68 were undetectable. While Bristol and Abbott also have regimens with high cure rates, they require more pills (3 drug DAA) and likely will require ribavirin."

Gilead Sciences closed at $73.92 on Monday.

Posted-In: Deutsche BankAnalyst Color Price Target Intraday Update Analyst Ratings

 

Most Popular

Related Articles (GILD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free